Fulcrum THerapeutics initiates phase III trial of losmapimod to treat COVID-19.
Fulcrum Therapeutics, Inc. announced that it received early notification from the FDA that the company may proceed with initiating a Phase III, randomized, double-blind, placebo-controlled trial of losmapimod… read more.